drugset

Drugs / Human CD19 targeted T Cells Injection

Follow last change Jan 2024 re-read 3 minutes ago

Human CD19 targeted T Cells Injection

Cell therapy targets CD19 via depletion

Developed for: B-cell acute lymphoblastic leukemia
Investigated by: Hrain Biotechnology Co., Ltd. · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Trials 1

today NCT03798509 · Ph 1

20192020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT03798509	Mar 2019 → Jan 2022	B-cell acute lymphoblastic leukemia	Hrain Biotechnology Co., Ltd.	Unknown	No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	Human CD19 targeted T Cells Injection	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03798509 ↗
Action	Deplete	“Chimeric antigen receptor T (CAR-T) cells are genetically modified T cells with redirected specificity and potent T-cell-mediated cytotoxicity toward malignant cells” PMID 36536403 ↗ Dec 2022
Modality	Cell therapy	“CAR-T cells are genetically modified T cells” PMID 36536403 ↗ Dec 2022
Target	CD19	“Autologous genetically modified anti-CD19 CAR transduced T cells” NCT03798509 ↗